

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
14 February 2019 (14.02.2019)



(10) International Publication Number
WO 2019/032743 A1

(51) International Patent Classification:

C07C 211/38 (2006.01) C07C 233/05 (2006.01)

C07C 217/52 (2006.01)

(21) International Application Number:

PCT/US2018/045868

(22) International Filing Date:

08 August 2018 (08.08.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/543,307 09 August 2017 (09.08.2017) US

62/553,728 01 September 2017 (01.09.2017) US

62/608,504 20 December 2017 (20.12.2017) US

(71) Applicant: DENALI THERAPEUTICS INC. [US/US];

151 Oyster Point Blvd., 2nd Floor, South San Francisco,
California 94080 (US).

(72) Inventors: CRAIG, Robert A., II; c/o Denali Therapeutics

Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francisco,
California 94080 (US). ESTRADA, Anthony A.; c/o
Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd
Floor, South San Francisco, California 94080 (US). FENG,
Jianwen A.; c/o Denali Therapeutics Inc., 151 Oyster Point
Blvd., 2nd Floor, South San Francisco, California 94080
(US). FOX, Brian; c/o Denali Therapeutics Inc., 151 Oyster
Point Blvd., 2nd Floor, South San Francisco, California
94080 (US). HALE, Christopher R. H.; c/o Denali Therapeutics
Inc., 151 Oyster Point Blvd., 2nd Floor, South San
Francisco, California 94080 (US). LEXA, Katrina W.; c/o
Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor,
South San Francisco, California 94080 (US). OSIPOV,
Maksim; c/o Denali Therapeutics Inc., 151 Oyster Point
Blvd., 2nd Floor, South San Francisco, California 94080
(US). REMARCHUCK, Travis; c/o Denali Therapeutics
Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francisco,
California 94080 (US). SWEENEY, Zachary K.;
c/o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd
Floor, South San Francisco, California 94080 (US). DE VI-
CENTE FIDALGO, Javier; c/o Denali Therapeutics Inc.,
151 Oyster Point Blvd., 2nd Floor, South San Francisco,
California 94080 (US).

(74) Agent: TANNER, Lorna L. et al.; Sheppard Mullin

Richter & Hampton LLP, 379 Lytton Avenue, Palo Alto,
California 94301-1479 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: COMPOUNDS, COMPOSITIONS AND METHODS

(57) Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.



WO 2019/032743 A1